The Myriad of Clinical Presentations of COVID-19: a Short Review

Richa Nepal

1Department of Internal Medicine, Bharatpur Hospital, Nepal

ABSTRACT

The ongoing pandemic of Coronavirus disease- 2019 is yet to be defeated. It is primarily a viral respiratory illness, with a myriad of clinical presentations being reported, since it was first identified towards the end of 2019 in China. Apart from the classical symptoms of fever, cough, and dyspnea, atypical presentations in COVID-19 patients, have puzzled healthcare workers worldwide. Patients with isolated non- respiratory complaints like diarrhea, vomiting, abdominal pain, skin rash, and confusion, have tested positive for severe acute respiratory syndrome coronavirus-2. The symptoms of olfactory and gustatory dysfunction have recently been added to the list for screening suspected cases after their prevalence was found to be high among COVID-19 patients. This article elaborates on the system-wise manifestations of COVID-19 and discusses the clinical implications of these aberrant presentations to healthcare workers.

Keywords: Coronavirus; COVID-19; Pandemic.

INTRODUCTION

Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is the ongoing pandemic that has challenged the global health system, destabilized human societies, and is taking a toll on the global economy. The clinical presentations of COVID-19 have been not less than a Pandora’s Box, with atypical presentations being reported worldwide. This article summarizes the clinical presentations of COVID-19 reported to date and tries to discuss the clinical implications of these myriads of phenotypes of COVID-19 patients.

COVID-19 CLINICAL FEATURES

Since COVID-19 was first identified in Wuhan, China; this novel disease has been found to have a wide clinical spectrum with classical involvement of the respiratory system to different other systems of the body. 50 to 88% of COVID-19 patients were asymptomatic at the time of testing in various studies, which is relevant because silent carriers are found to amplify viral dissemination to communities. The commonest clinical features that were seen in symptomatic COVID-19 patients in various studies from China, United Kingdom, Pakistan, and India, have been listed in Table 1. In a study by Tambe et al. from Pune, Maharashtra, 57.4% of patients were afebrile at the time of presentation and 56.5% did not have cough.

Table 1. Common clinical presentations in COVID-19 patients in different studies

| Symptoms               | Guan et al. | Docherty et al. | Asghar et al. | Tambe et al. |
|------------------------|-------------|-----------------|---------------|--------------|
| Fever                  | 88.7%       | 69%             | 83%           | 42.6%        |
| Dry cough              | 67.8%       | 70%             | 52%           | 43.5%        |
| Sputum production      | 33.7%       | 25%             | 18%           | 5.6%         |
| Fatigue                | 38.1%       | 37.5%           | 16%           | 5.1%         |
| Dyspnea                | 18.7%       | 65%             | 43%           | 46.7%        |
| Sore throat            | 13.9%       | 12%             | 16%           | 2%           |
| Headache               | 13.6%       | 15%             | 8%            | 2.5%         |
| Nausea/ vomiting       | 5%          | 18%             | 13%           | 5.1%         |
| Diarrhea               | 5%          | 20%             | 17%           | 1%           |
Table 2 enlists the case fatality rate (CFR) of COVID-19 in different countries by 3rd June, 2020. Nepal has reported a total of 8 COVID-19 related deaths out of 2,099 patients by 3rd June, 2020. However, the CFR may be confounded by factors like the current stage of disease transmission in a specific country, the magnitude of testing and reporting of deaths in that particular country.

| Country | France | Italy | UK | USA | China | Iran | Germany | India | Russia | Nepal |
|---------|--------|-------|----|-----|-------|------|---------|-------|--------|-------|
| CFR (%) | 19.52  | 14.35 | 14.16 | 5.83 | 5.49   | 5.04 | 4.68    | 2.80  | 1.20   | 0.0038 |

**SYSTEM-WISE MANIFESTATIONS**

The system-wise manifestations of COVID-19, with the reported atypical signs and symptoms, have been elaborated below:

**Respiratory system**

The disease may present as mild upper respiratory tract infection to lower respiratory tract involvement in the form of pneumonia and acute respiratory distress syndrome. COVID-19 pneumonia is a specific disease entity different from classical ARDS as despite severe hypoxemia in patients, lung compliance was surprisingly found to be near normal (unlike in cases of typical ARDS). Heterogeneous presentation of COVID-19 pneumonia has been observed with normal breathing (silent hypoxia) and very dyspeptic phenotypes. Apart from cough and dyspnea, hemoptysis has been reported in 1 to 5% hospitalized COVID-19 patients and when present, it warrants evaluation for possible pulmonary embolism.

**Gastrointestinal system**

Incidence of diarrhea in cases of COVID-19 ranged from 2% to 50%, which may precede or follow respiratory symptoms. In a case series by Pan et al., from Hubei province, China; 18.6% of patients presented with a gastrointestinal specific symptom which included diarrhea, vomiting, or abdominal pain. Around 2.9% of those patients, had digestive symptoms without respiratory symptoms. Likewise, a patient in France, with the only presenting complaint of acute abdominal pain, was reported to have COVID-19. A nasopharyngeal swab of that patient was sent for reverse transcriptase-polymerase chain reaction test, only after the abdominal computerized tomography revealed subpleural irregular lines and peribronchial opacities at lung bases leading to suspicion of COVID-19.

**Neurological system**

COVID-19 can present with encephalopathy, more common in eldersies, and in critically ill patients. Encephalopathy may be specific to SARS-CoV-2 infection or may be secondary to multi-organ failure, cytokine storm, metabolic abnormalities or effect of drugs. Nearly one-fourth of patients had some form of neurological manifestations ranging from headache, agitation, and confusion to cerebrovascular events like cerebral hemorrhage and infarction. Clinical case reports of large vessel strokes and Guillain-Barre syndrome, being the presenting features in COVID-19 patients are reported, though the causal association is yet to be proved. With the demonstration of SARS-CoV-2 in CSF of COVID-19 patients with neurological symptoms, neuroinvasion by the virus seems to be a plausible hypothesis that needs further testing.

Evidence suggests that olfactory and gustatory symptoms were common among mild to moderate COVID-19 patients. Hyposmia/anosmia and dysgeusia/ageusia were added to the list of symptoms, for the screening of potential COVID-19 infection, by World Health Organization on May 6th, 2020. SARS-CoV-2 is believed to invade olfactory bulb and epithelium, leading to impairment of smell sensation even without nasal obstruction. An atypical case of sudden and complete loss of olfactory function has also been reported in a COVID-19 patient. In a study by Lechien et al., 85.6% of patients, had olfactory symptoms which were reported after, during, and even before other symptoms had appeared. High prevalence of these symptoms, with 11.8% cases, exhibiting olfactory dysfunction before the appearance of other complaints; is a relevant finding to aid for early detection of COVID-19.

**Cardiovascular system**

The acute cardiac injury was present in 20% COVID-19 cases, which was associated to increased mortality. With myocardial localization of coronavirus, documented in a critically ill patient in Italy, the mechanism for acute cardiac injury is postulated to be either due to direct viral invasion or cytokine storm resulted from hyperimmune host response. In a case series from New York, 33% patients who presented with ST-segment elevation in ECG and symptomatology of chest pain, without fever or respiratory complaints; had non-obstructive coronaries in coronary angiography, and were positive for SARS-CoV-2. Thus, the threshold for SARS-CoV-2 testing must be kept low, in patients presenting with features like myopericarditis and cardiogenic shock, even in absence of respiratory complaints, during the time of this pandemic. Another important fact, that needs to be emphasized, is the pro-arrhythmogenic potential of drugs like azithromycin, hydroxychloroquine, chloroquine, and antivirals, that are being compassionately used for COVID-19 patients, which if not monitored may lead to catastrophic cardiac events.

**Hematopoietic system**

On comparing hematological parameters between survivors and non-survivors of COVID-19, higher leukocyte counts, and lower platelet counts were found in non-survivors. The increase in leucocyte count was largely driven by neutrophilia, whereas a decreasing trend was noted for lymphocytes, monocytes, and eosinophils. Coagulopathy was common in patients of COVID-19, as reflected by the observation that criteria for disseminated intravascular coagulation, was met in 71.9% of non-survivors in study. Despite the coagulopathy, COVID-19 primarily presented as a thrombotic entity, rather than bleeding diathesis. Incidence of arterial and venous thrombotic events ranged from 31 to 57% in critically ill patients in various studies, with pulmonary embolism being the commonest. Elevated D-dimer levels, thrombocytopenia, prolonged prothrombin,
Clinical Presentations of COVID-19

Renal system

Acute kidney injury, in COVID-19, may result from acute tubular necrosis due to dehydration, sepsis, cytokine storm, use of multiple drugs, hypoxia, or rhabdomyolysis. 75.4% of hospitalized COVID-19 patients had renal involvement in the form of abnormal urine dipstick tests, or AKI. Proteinuria and hematuria were found in 44% and 26% of hospitalized patients, respectively. The prognostic implication of kidney dysfunction is higher overall mortality among patients with renal involvement, as compared to those without renal involvement (11.2% versus 1.2%).

Hepatic system

Aminotransferase levels were reported abnormal in 14 to 53% of hospitalized COVID-19 patients, with abnormal levels being more common in severe forms of the disease. However, clinically significant liver dysfunction was not present, even among the most severely ill patients.

Cutaneous manifestations

Macular, maculopapular or morbilliform rashes, urticarial, petechial, and ischemic acral lesions, have been documented in COVID-19 patients, who had minimal other complaints. Skin lesions may be due to direct viral invasion, systemic effects of infection, or secondary to use of drugs. Skin manifestations were present even before other symptoms appear, yielding them useful for early detection of COVID-19. There have been reports, that in the background of fever, thrombocytopenia and petechial rash, cases of COVID-19 were mistaken for dengue fever, in endemic areas leading to delay in diagnosis of the disease proper.

Clinical implications

World Health Organization strongly recommends trace, isolate, test, and treat policy, for every suspected case to break the chains of COVID-19 transmission. COVID-19 is reported to have various non-respiratory signs and symptoms, which may precede classical respiratory complaints. The absence of fever or cough, in any patient, should not be presumed as an exclusion criterion for COVID-19. The definition of clinical COVID-19 patient has been dynamically changing, with rapidly evolving research about this novel disease. Patients with typical cardiac events, isolated complaints of acute abdomen, encephalopathy, cutaneous manifestations, oligo and gustatory dysfunction, are reported to have a positive SARS-CoV-2 test. These aberrant presentations can be grossly missed by healthcare workers, resulting in further dissemination of virus in the communities. Thus, healthcare workers must be updated of all possible ways, by which COVID-19 may present. Likewise, it is imperative that the threshold for testing for SARS-CoV-2 must be kept low during the time of pandemics like today, to diagnose patients with aberrant presentations.

CONCLUSIONS

COVID-19 has a myriad of clinical presentations, affecting different systems of the human body. Healthcare workers need to have a high degree of clinical suspicion for patients with atypical presentations so that they can be identified at the earliest, and necessary clinical and public health measures can be taken to contain the virus and beat this pandemic of COVID-19.

REFERENCES

1. Legido-Quigley H, Asgari N, Teo YY, Leung GM, Oshitani H, Fukuda K, et al. Are high-performing health systems resilient against the COVID-19 epidemic? The Lancet. 2020;395(10227):848-50. DOI: CrossRef
2. Sutton D, Fuchs K, D’alton M, Goffman D. Universal screening for SARS-CoV-2 in women admitted for delivery. N Engl J Med 2020; 382:2163-2164. CrossRef
3. Arons MM, Haftfield KM, Reddy SC, Kimball A, James A, Jacobs JR, et al. Presymptomatic SARS-CoV-2 infections and transmission in a skilled nursing facility. N Engl J Med 2020; 382:2081-2090. CrossRef
4. Guan WJ, Yi ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020; 382:1708-20. CrossRef
5. Docherty AB, Harrison EM, Green CA, Hardwick HE, Pius R, Norman L, et al. Features of 16,749 hospitalised UK patients with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol. medRxiv 2020.04.23.20076042; CrossRef
6. Asghar MS, Kazmi SJ, Khan NA, Akram M, Khan SA, Rasheed U, et al. Clinical Profiles, Characteristics, and Outcomes of the First 100 Admitted COVID-19 Patients in Pakistan: A Single-Center Retrospective Study in a Tertiary Care Hospital of Karachi. Cureus 2020;12(6):e8712. CrossRef
7. Tambe MP, Parande MA, Tapare VS, Borle PS, Lakde RN, Shelke SC. An epidemiological study of laboratory confirmed COVID-19 cases admitted in a tertiary care hospital of Pune, Maharashtra. Indian Journal of Public Health. 2020 Jun 1;64(6):183. CrossRef
8. World Health Organization. Coronavirus disease 2019 (COVID-19): situation report, 135. (Cited on 3rd June 2020) Available from: Website
9. Gattinoni L, Chiumello D, Caironi P, Busana M, Romitti F, Brazzi L, et al. COVID-19 pneumonia: different respiratory treatments for different phenotypes? Intensive Care Med 2020;46:1099–102. CrossRef
10. Casey K, Iteen A, Nicolini R, Auten J. COVID-19 pneumonia with hemoptysis: Acute segmental pulmonary emboli associated with novel coronavirus infection. Am J Emerg Med. 2020; 38(7): 1544.e1–1544.e3. CrossRef
11. D’Amico F, Baumgart DC, Danese S, Peyrin-Biroulet L. Diarrhea during COVID-19 infection: pathogenesis, epidemiology, prevention and management. Clin Gastroenterol Hepatol 2020 Jul;18(8):1663-72. CrossRef
12. Pan L, Mu M, Yang P, Sun Y, Wang R, Yan J, et al. Clinical characteristics of COVID-19 patients with digestive symptoms in Hubei, China: a descriptive, cross-sectional, multicenter study. The American journal of gastroenterology. 2020;115:766-73. CrossRef

Nepal et al.
13. Gahide G, Frandon J, Vendrell JF. COVID-19 patients presenting with afebrile acute abdominal pain. Clinical Medicine. 2020;20(3):e4-6. Crossref

14. Helms J, Kremer S, Merdji H, Clerc-Jebl R, Schenck M, Kummerlen C, et al. Neurologic features in severe SARS-CoV-2 infection. N Engl J Med 2020; 382:2268-70. Crossref

15. Asadi-Pooya AA, Simani L. Central nervous system manifestations of COVID-19: A systematic review. J Neurol Sci. 2020;413:116832. Crossref

16. Oxley TJ, Mocco J, Majidi S, Kellner CP, Shoirah H, Singh IP, et al. Large-vessel stroke as a presenting feature of Covid-19 in the young. N Engl J Med. 2020;382(20):e60. Crossref

17. Toscano G, Palermiini F, Ravaglia S, Ruiz L, Invernizzi P, Cuzzoni MG, et al. Guillain–Barré syndrome associated with SARS-CoV-2. N Engl J Med. 2020;382(26):2574-6. Crossref

18. Beijing hospital confirms nervous system infections by novel coronavirus. Xinhua [newspaper on the internet]. 2020 March 3. [cited 2020 June 3]; Home. Available from: Website

19. American Academy of Otolaryngology - Head and Neck Surgery. Coronavirus disease 2019:resources. 2020 [internet publication]. Available from: Website

20. Eliezer M, Hautefort C, Hamel AL, Verillaud B, Herman P, Houdart E, et al. Sudden and complete olfactory loss function as a possible symptom of COVID-19. JAMA Otolaryngol Head Neck Surg. 2020 Apr 8. Crossref

21. Lechien JR, Chiesa-Estomba CM, De Siati DR, Horoi M, Le Bon SD, Rodrigues A, et al. Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study. Eur Arch Otorhinolaryngol. 2020;277(8):2251-61. Crossref

22. Tavazzi G, Pellegrini C, Maurelli M, Belliato M, Sciutti F, Bottazzi A, et al. Myocardial localization of coronavirus in COVID-19 cardiogenic shock. Eur J Heart Fail. 2020;22(5):911-5. Crossref

23. Bangalore S, Sharma A, Slotwiner A, Yartey N, Dave M, Lee K, Hart DP, et al. Lupus Anticoagulant and Abnormal Coagulation Tests in Patients with Covid-19. N Engl J Med. 2020 May 5;NEJMc2013656. Crossref

24. Bowles I, Platton S, Yartey N, Dave M, Lee K, Hart DP, et al. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020;18(4):844-847. Crossref

25. Klok FA, Kruip MJ, Van der Meer NJ, Arbous MS, Gommers DA, Kant KM, et al. Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: An updated analysis. Thromb Res. 2020 07; 191:145-147. Crossref

26. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020;18(4):844-847. Crossref

27. Valizadeh R, Baradaran A, Mirzaazadeh A, Bhaskar LV. Coronavirus-nephropathy; renal involvement in COVID-19. J Ren Inj Prev Coronavirus-Nephropathy. 2020;5(3):428-430. Crossref

28. Zhang C, Shi L, Wang FS. Liver injury in COVID-19: management and challenges. Lancet Gastroenterol Hepatol. 2020;5(5):428-430. Crossref

29. Recalcati S. Cutaneous manifestations in COVID-19: a first perspective. J Eur Acad Dermatol Venereol. 2020;34(5):e212-e213. Crossref

30. Piccolo V, Neri I, Filippeschi C, Oranges T, Argenziano G, Battarra VC, et al. Chilblain-like lesions during COVID-19 epidemic: a preliminary study on 63 patients. J Eur Acad Dermatol Venereol. 2020;34(5):e212-e213. Crossref

31. WHO urges countries to ‘trace and test’ every COVID-19 case. The Guardian. [newspaper on the internet]. 2020 May 13 [cited 2020 June 3]; World. Available from: Website